{"id":"tp-50745","type":"article-newspaper","title":"Latigo Biotherapeutics’ Q3 Loss Per Share Beats Estimate by $0.12","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/50745","datePublished":"2026-11-07T10:18:39.000Z","dateModified":"2026-11-07T10:18:39.000Z","language":"en","abstract":"The company expects $401 million in cash and cash equivalents to fund operations into 2029.","section":"Business","references":[]}